MCM
ANIK icon

Mazama Capital Management’s Anika Therapeutics ANIK Stock Holding History

Mazama Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,028
Closed -$42K – 270
2014
Q1 		$42K Buy
+1,028
New +$38.2K 0.04% 161

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Mazama Capital Management's ANIK Position: Q2 2014 in Review

Mazama Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2014, closing a stake of 1,028 shares — an estimated $42K sold.

Mazama Capital Management first reported a position in ANIK in Q1 2014 and held it in 1 quarter. The position peaked at $42K in Q1 2014. 162 funds tracked by Wall St. Rank hold ANIK as of Q2 2014.

  • Mazama Capital Management reported no remaining Anika Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Mazama Capital Management sold 1,028 Anika Therapeutics shares in Q2 2014, an estimated $42K.
  • Mazama Capital Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 1 quarter.
  • Mazama Capital Management's Anika Therapeutics position peaked at $42K in Q1 2014.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2014.

Based on Mazama Capital Management's 13F filing for Q2 2014, filed 28 Jul 2014.